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MicroRNA-128-2 targets the transcriptional repressor
E2F5 enhancing mutant p53 gain of function
S Donzelli1, G Fontemaggi1,2, F Fazi3, S Di Agostino1, F Padula4, F Biagioni1, P Muti5,7, S Strano6 and G Blandino*,1
p53 mutations have profound effects on non-small-cell lung cancer (NSCLC) resistance to chemotherapeutic treatments.
Mutant p53 proteins are usually expressed at high levels in tumors, where they exert oncogenic functions. Here we show
that p53R175H, a hotspot p53 mutant, induces microRNA (miRNA)-128-2 expression. Mutant p53 binds to the putative
promoter of miR128-2 host gene, ARPP21, determining a concomitant induction of ARPP21 mRNA and miR-128-2. miR-128-2
expression in lung cancer cells inhibits apoptosis and confers increased resistance to cisplatin, doxorubicin and 5-fluorouracyl
treatments. At the molecular level, miR-128-2 post-transcriptionally targets E2F5 and leads to the abrogation of its repressive
activity on p21waf1 transcription. p21waf1 protein localizes to the cytoplasmic compartment, where it exerts an anti-apoptotic
effect by preventing pro-caspase-3 cleavage. This study emphasizes miRNA-128-2 role as a master regulator in NSCLC
chemoresistance.
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Mutations in the TP53 gene are the most frequent type of
gene-specific alterations in human cancers.1 The majority of
cancer-associated mutations in TP53 gene are missense
mutations that reside mainly in the exons encoding for p53
DNA-binding domain.2 These mutations frequently result in
full-length mutant p53 proteins incapable of activating p53
target genes and suppressing tumorigenesis.3 Most TP53
mutations can be classified into two main categories accord-
ing to their effect on the thermodynamic stability of the p53
protein.4 These two mutation categories are commonly referred
to as DNA-contact and conformational mutations. The first group
includes mutations in residues directly involved in DNA binding,
such as R248Q and R273H. The second group comprises
mutations that cause local (such as R249S and G245S) or
global (such as R175H and R282W) conformational distortions.
Besides losing their wild-type (wt) activities, mutant p53
proteins have also dominant-negative effects that inactivate
wt p53 protein expressed from the remaining wt allele.
Moreover, some mutant p53 forms also acquire new
oncogenic properties – ‘gain of function’ – that overrule those
due to loss of wt p53 activity by gene deletion.5–7 These
properties range from enhanced proliferation in culture and
resistance to a variety of anticancer drugs commonly used in
the clinical practice, to increased tumorigenicity in vivo.8–10
Recent work indicates that mutant p53 protein can augment
in vitro and in vivo cell migration and invasion.11 Fontemaggi
et al.12 showed that mutant p53 increases also the angiogenic
potential of cancer cells by modulating, at the transcriptional
level, Id4 expression.
The existing knowledge regarding the molecular mechan-
isms whereby mutant p53 regulates gene expression is still
lacking. To date, we can depict the three following molecular
scenarios to explain gain-of-function of mutant p53 proteins:
(i) mutant p53 binds to the promoter of its target genes by
interacting with other transcription factors and contribute to
transcriptional modulation through its intact transactivation
domain. In support to this molecular mechanism it has been
reported that human tumor-derived p53 mutants whose TAD
was inactivated by site-directed mutagenesis, lost the ability
to increase tumorigenicity in vitro and in vivo.1,13–15 Several
sequence-specific transcription factors, such as Sp1,16 Ets
proteins family,17 NF-Y,18 VDR, p65NF-kB and E2F1,12 have
been shown to interact with mutant p53 so far. (ii) Mutant p53
binds to and sequesters proteins with antitumor activity, such
as growth inhibition or apoptosis induction. At this regard, it
has been demonstrated that mutant p53 binds to its family
members, p63 and p73, impairing their transcriptional activity
and consequently their antitumoral effects.19–22 (iii) Mutant
p53 protein, for which the attempts to delineate a specific
DNA-binding sequence distinct from those regulated by wt
p53 have failed, has been reported to directly bind a wide
range of DNA secondary structures, such as matrix attach-
ment regions with a high potential of base unpairing in vitro,23
or non-B DNA structures.24 This might imply that chromatin
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remodeling may be involved in transcriptional activities
mediated by mutant p53 protein.
In the present study, we explored the possibility that mutant
p53 protein, in addition to the transcriptional modulation of
genes involved in the control of tumorigenesis, exerts its gain-
of-function activity by modulating the expression of microRNAs
(miRNAs). miRNAs are 22-nucleotides-long double-strand
small RNAs able to modulate gene expression at post-
transcriptional level, degrading mRNA and/or impairing trans-
lation.25 Many data suggest that miRNAs are key components
of a wide range of biological processes, including pathways
leading to neoplastic transformation.26 In particular, the
involvement of miRNAs in the pathogenesis of cancer was
suggested by the observation that changes in miRNAs
expression patterns, as well as recurrent amplification/deletion
at their loci, are frequent events in human tumors.27–29
By screening the expression of miRNAs known to be
deregulated in lung cancer,28 in a human non-small-cell lung
cancer (NSCLC) cell line (H1299) expressing the inducible
mutant p53His175 protein, we found that the expression of
intragenic miR-128-2 increases upon mutant p53His175 protein
induction. We observed that mutant p53His175 is recruited on
the promoter region of miR128-2 host gene,ARPP21, determin-
ing a concomitant induction of ARPP21 mRNA level.
The expression of the transcriptional repressor E2F5, a
target of miR-128-2, strongly decreases after miR-128-2
exogenous expression. This leads to the abrogation of E2F5
repressive activity on p21waf1 promoter and, consequently, to
the transcriptional induction of p21waf1. The newly synthe-
sized p21waf1 protein is mainly localized into the cytoplasmic
compartment, where it exerts an anti-apoptotic function in
response to anticancer drug treatments. Interestingly, miR-128-2
effects are observed also in p53-wt and p53-null cells.
These data indicate that miR-128-2 modulation contributes
to mutant p53His175 gain-of-function activity by conferring
increased chemoresistance of lung cancer cells.
Results
Mutant p53His175 induces miR-128-2 expression. To
investigate whether mutant p53 proteins exert gain-of-
function activity through the modulation of miRNAs
expression, we screened human NSCLC cells carrying
ponasterone (Pon-A)-inducible mutant p53His175 (H1299
no. 41) protein for the expression of a panel of miRNAs
differentially represented in lung cancers versus normal
tissues (Figure 1a).28 As shown in Figure 1a and
Supplementary Figure 1A, mutant p53 upregulates the
expression of miR-128-2. Pon-A-inducible wt p53
(H1299#23) has no effect on miR-128-2 expression,
indicating that miR-128-2 is specifically regulated by mutant
p53 protein. As control, miR-128-2 expression is also
unchanged in H1299 cells transduced with the vectors
of the Pon-A-inducible system (H1299-pIND; Figure 1b).
miR-128-2 is accumulated in a time-dependent manner
(Figure 1c). We found that the precursor of miR-128-2
(pre-miR-128-2) was also induced by mutant p53; thereby
suggesting that mutant p53 could control miR-128-2
expression at the transcriptional level (Figure 1d). miR-128-2
is an intragenic miRNA located within the 18th intron of
ARPP21 gene.30 The analysis of ARPP21 gene expression
evidences that ARPP21 mRNA is induced, to a similar extent
than that of miR-128-2, following mutant p53His175
expression (Figure 1e and Supplementary Figure 1B).
Altogether, these findings indicate that mutant p53 protein
controls the expression of both miR-128-2 and ARPP21
through a common transcriptional regulatory mechanism.
Mutant p53 binds to and transactivates ARPP21
promoter. It has been shown that gain-of-function mutant
p53 proteins acquire the ability to directly regulate gene
expression by binding to the promoter of their target genes in
cooperation with other transcription factors (Sp1, NF-Y,
E2F1, cEts).12,16–18 We then investigated by chromatin
immunoprecipitation assay the recruitment of mutant p53 to
miR-128-2 regulatory regions.
As intragenic miRNAs can be either controlled by the
promoter of their host gene or by their own promoter,31 we
performed bioinformatic analyses searching for both promoter
regions and transcription start sites (TSS) on the yet
uncharacterized ARPP21 gene locus, by using Genomatix
(http://www.genomatix.de) and Dragon Promoter Finder
(http://mybio.wikia.com/wiki) software. A schematic representa-
tion of the identified putative promoter and TSSs, as well as the
position of the primers used in chromatin immunoprecipitation
(ChIP) assay, is shown in Figure 2a. We found that mutant
p53 binds to three regions of the putative ARPP21 promoter
(indicated as 1, 3 and 6 in Figures 2a and b), whereas no
mutant p53 recruitment was observed in the upstream regions
of miR-128-2, located in the 18th intron of ARPP21 gene
(Figure 2b).
Next, we performed transactivation assays using two
different constructs of the ARPP21 promoter, one enclosing
the putative TSS and one with the region upstream the first
exon (Figure 2c). We observed that mutant p53 was able to
transactivate the ARPP21 promoter region enclosing the
putative TSS (Figure 2d). This transactivation effect was
dose-dependent (Figure 2e).
Altogether, these data suggest that miR-128-2 and
ARPP21 mRNA could be generated by a common precursor.
This event is frequently observed for intronic miRNAs and
their host genes.
miR-128-2 confers chemoresistance to lung cancer cell
lines. To further investigate the contribution of miR-128-2
modulation to mutant p53 gain-of-function activity, we
assessed whether miR-128-2 exogenous expression
impacts on the response of two lung cancer cell lines,
H1299 and A459, to doxorubicin (DOXO), cisplatinum
(CDDP) and 5-fluorouracil (5-FU).
We observed that miR-128-2 expression reduces the sub-G1
cell population in both cell lines after chemotherapeutic
treatments (Figure 3a and b and Supplementary Figure 2).
Counting of Trypan blue-positive cells in the same experimental
conditions confirmed thatmiR-128-2 expression confers chemo-
resistance to CDDP and DOXO in H1299 cells (Figure 3c).
Furthermore, the analyses of the cleaved fragment of
PARP (p85), a well-known substrate for caspase-3 cleavage
during apoptosis, confirmed that the exogenous expression of
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miR-128-2 reduces the apoptotic rate of both H1299 and A459
cell lines upon DOXO and 5-FU treatments (Figures 3d and e).
Conversely, we observed an increase of both PARP p85 and
cleaved caspase 3 expression upon DOXO and cisplatin
treatment in H1299 cells when endogenous miR-128-2 has
been sequestered by the transfection of a decoy-vector,
carrying tandem repeat complementary sequences of
miR-128-2 (Figures 3f and g). These results indicate that
miR-128-2 expression confers chemoresistance to cancer
cells and this effect is independent from the p53 status as
occurs in both p53-null (H1299) and p53-wt (A459) cells.
miR-128-2 targets the transcriptional repressor E2F5. By
using two prediction algorithms, TargetSCAN (http://
www.targetscan.org) and PicTar (http://pictar.mdc-berlin.de/),
we identified the transcriptional repressor E2F5 as putative
target for miR-128-2 (Figure 4a). The E2F family of
transcription factors is an important class of cellular
regulators that behave as both oncogenes and tumor
suppressor genes in a context-specific manner.32 E2Fs can
be broadly classified as activators (E2F1, E2F2, and E2F3A)
or suppressors/antagonists (E2F3B, E2F4, E2F5, E2F6,
E2F7, and E2F8).33 This classification refers primarily to
the ability of the E2Fs to activate or inhibit transcription
mediated through E2F response elements. To experi-
mentally test whether our predicted target was regulated
by miR-128-2, we analyzed E2F5 expression in H1299
cells transfected or not with miR-128-2 precursor. Because
of the inability of two different antibodies to detect the
endogenous E2F5 protein by western blot analysis, we
analyzed its expression after immunoprecipitation-mediated
enrichment. As shown in Figure 4b and Supplementary
Figure 3, only one of the tested antibodies (ab_1) was
capable to immunoprecipitate the expected 36 kDa form of
Figure 1 p53His175 transcriptionally induces the expression of miR-128-2 and of its host gene, ARPP21. (a) Quantitative RT-PCR (qRT-PCR) analysis of 11 miRNAs
expression in H1299-p53His175 inducible system (H1299#41) upon 24 h of ponasterone treatment. (b) qRT-PCR analysis of miR-128-2 expression on H1299#41 (expressing
inducible p53-R175H), H1299 carrying the empty vector (H1299-pIND), H1299#23 (expressing inducible wild-type p53) cells in the presence or absence of ponasterone (24 h).
p53 protein induction was assessed by western blotting (below). (c) qRT-PCR analysis of miR-128-2 expression on H1299#41 upon 24–36–48 h of ponasterone treatment.
MicroRNAs expression levels were normalized over RNU6b expression. (d) RT-PCR analysis of pre-miR-128-2 expression in H1299-p53His175 inducible system upon 48 h of
ponasterone treatment. (e) qRT-PCR analysis of ARPP21 expression in H1299-p53His175 inducible system upon 48 h of ponasterone treatment
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E2F5 (Figure 4b and Supplementary Figure 3, control
samples). miR-128-2 exogenous expression strongly
reduced the amount of the immunoprecipitated E2F5
protein in H1299 cells (Figure 4b). This reduction was also
observed when E2F5 protein staining was analyzed by
immunocytochemistry (Figure 4c and Supplementary Figure 4,
panel A). To formally demonstrate that miR-128-2 targets
E2F5 mRNA, the E2F5-30-UTR was cloned downstream the
Renilla luciferase gene in the pRL-TK vector (pRL-TK-E2F5-
30-UTR). As shown in Figure 4d miR-128-2 transfection
significantly decreased the Renilla luciferase activity of the
vector enclosing E2F5-30-UTR.
As in the cells transfected with miR-128-2, we also
observed a reduction of E2F5 protein level in H1299#41 cells
following mutant p53His175 induction (Figure 4e). E2F5
protein decrease after mutant p53 expression was also
assessed by immunocytochemistry in the same experimental
conditions (Supplementary Figure 4b).
miR-128-2 induces p21waf1 expression and cytoplasmic
localization in lung cancer cell lines. It is well established
that sensitivity to chemotherapeutic treatments is strongly
linked to cell cycle regulation. When the effect of miR-128-2
exogenous expression on cell cycle regulatory proteins was
evaluated we found that p21waf1 expression is induced by
miR-128-2 in H1299 (p53-null) and A459 (p53-wt) cells at
both mRNA and protein levels (Figures 5a and b). p21waf1
induction also occurs in H1299#41 after induction of
mp53His175 protein that upregulates miR-128-2 expression
(Figures 5a, b and 1b). The observed induction of p21waf1 in
A459 cells seems not to be mediated by endogenous wt p53,
as no p53 protein stabilization was observed after miR-128-2
exogenous expression (Supplementary Figure 5). These
observations indicate that miR-128-2-dependent p21
induction, as the above-described miR-128-2-mediated
chemoresistance, is independent of p53 status.
By using the MatInspector software (http://www.genomatix.
de/en/index.html), we identified the presence of binding sites
for the E2F family of transcription factors on p21waf1 promoter.
To evaluate whether the transcriptional repressor E2F5 binds
to p21waf1 promoter, we performed ChIP experiments. We
observed that E2F5 binds to p21waf1 promoter in H1299 cells
(Figure 5c, left). Exogenous expression of miR-128-2
releases E2F5 occupancy of p21waf1 promoter (Figure 5c,
right). This pairs with the decrease of E2F5 protein levels in
the same experimental condition (shown in Figure 4b and c)
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Figure 2 p53His175 binds to and transactivates ARPP21 regulatory regions. (a) Schematic representation of ARPP21 gene: three different regions have been analyzed in
ChIP assays; one of 2 kb upstream the first exon of ARPP21, for which six couples of primers that amplified adjacent regions have been drawn (1–6); one at 7 kb upstream
miR-128-2 mature sequence in which according to Dragon Promoter Finders software analysis a putative TSS is present (indicated as 7); one upstream the 50 of mir-128-2
mature sequence (indicated as 8). (b) Cross-linked chromatin from proliferating H1299-p53His175 inducible cells, untreated or treated with ponasterone for 48 h, was
immunoprecipitated with an antibody (Ab) to p53 or in the absence of antibody, and analyzed by PCR with primers specific for the indicated regions (see Materials and
Methods). Input, non-immunoprecipitated cross-linked chromatin. (c) Schematic representation of the plasmids used in the luciferase experiments (d and e). (d) H1299-
p53His175 inducible cells were transiently transfected with two constructs carrying the luciferase reporter gene driven by two adjacent regions of ARPP21 promoter; one
enclosing the putative TSS (A-luc) and one enclosing the upstream region of first exon (B-luc) and treated for 24 or 48 h with ponasterone. (e) H1299 cells were transiently
transfected with A-luc construct and increasing amounts of pcDNA3 vector containing p53His175 cDNA. An equal amount of CMV-b-gal was added to each transfection
mixture. Cell extracts were prepared 48 h later and subjected to determination of luciferase activity. Results are presented as luciferase activity (Luc) relative to total proteins
and b-galactosidase (b-gal) activity. Histograms show the mean of three experiments performed in duplicate
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and indicates that E2F5 is involved in the trans-
criptional modulation of p21 observed after miR-128-2
overexpression.
In agreement with a role for miR-128-2 in the control of p21
expression, the transfection of a specific decoy for miR-128-2
in p53His175-inducible H1299 cells prevents p21waf1 protein
accumulation (Figure 5d). The analysis of p21waf1 protein
half-life revealed that the protein is more stable upon
miR-128-2 exogenous expression (Figure 5e). Within the
same experimental conditions, we found that the half-life of
cyclin D1, a protein involved in the promotion of p21waf1
stability,34 was also extended, thereby suggesting that miR-
128-2 promotes both the induction of p21waf1 transcript as well
as the maintenance of p21waf1 protein stability.
Figure 3 miR-128-2 confers chemoresistance to lung cancer cell lines. (a and b) Percentage of cells in sub-G1 phase obtained by FACS analysis performed in H1299 and
A459 cells after 48 h of transfection with 5 nM miR-128-2 mimic or control mimic, and 24 h of treatment with 2,5mM doxorubicin (DOXO), 5 and 10mg/ml cisplatinum (CDDP),
and 50mg/ml 5-fluorouracil (5-FU). Histograms show the mean of three experiments performed in duplicate. Mir-128-2 relative expression levels were evaluated by qRT-PCR
(right graph). (c) Cell killing was measured by Trypan blue assay 48 h after transfection with 5 nM miR-128-2 mimic or control mimic in H1299 treated for 24 h with 10 mg/ml
CDDP and 2,5mM DOXO. Data are shown as means±S.D. of triplicate counts. Mir-128-2 relative expression levels were evaluated by qRT-PCR (right graph). (d and e)
Cleavage of the caspase substrate PARP in H1299 and A459 cells transfected with miR-128-2 mimic or control mimic and treated for 24 h with 2.5mM DOXO and 50mg/ml
5FU, respectively. Mir-128-2 relative expression levels were evaluated by qRT-PCR (low graphs). (f and g) Cleavage of the caspase substrate PARP in H1299 cells transiently
transfected with decoy-miR-128-2 or decoy-control vectors and treated for 24 h with 2.5mM DOXO and 10mg/ml CDDP. The amounts of cleaved caspase-3 were analyzed by
western blot using a specific antibody to caspase-3. MiR-128-2 sequestration was controlled by western blot analysis of GFP protein expression
miR-128-2 enhances chemoresistance in NSCLC
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p21waf1 has been shown to exert dual and opposite effects,
depending on its subcellular localization. Indeed, p21waf1
nuclear localization promotes growth arrest, while its cyto-
plasmic accumulation prevents apoptosis through the inter-
action and the suppression of pro-caspase-3.35 Because of
these opposite roles of p21waf1 depending on its subcellular
localization and to the observed miR-128-2-dependent anti-
apoptotic effect, we analyzed p21waf1 subcellular localization
upon miR-128-2 overexpression. We observed, by cell
fractionation (Figure 5f) and immunofluorescence
(Figure 5g), that p21waf1 accumulates in the cytoplasm
of both H1299 and A459 cell lines following miR-128-2
exogenous expression. We therefore analyzed p21waf1
and caspase-3 subcellular localization after miR-128-2
expression. As shown in Figure 6a, we observed that
p21waf1 and pro-caspase-3 colocalize in the cytoplasm,
thereby suggesting the involvement of p21waf1 in the inhibition
of pro-caspase-3 cleavage following miR-128-2 exogenous
expression.We found that exogenous expression of miR-128-2
reduces pro-caspase-3 cleavage in both H1299 and A459
cell lines upon CDDP (left) and 5-FU (right) treatment,
respectively (Figure 6b). We also found that mutant p53
expression, which leads to p21waf1 induction, markedly
reduces DOXO-induced PARP cleavage (Figure 6c, left).
On the contrary, exogenous expression of a specific decoy for
miR-128-2 impairs p21waf1 protein induction and renders
mutant p53-expressing cancer cells less prone to the killing by
DOXO (Figure 6c, right).
Figure 4 mir-128-2 targets the transcriptional repressor E2F-5. (a) Predicted duplex formation between human E2F5-30-UTR and miR-128-2. (b) Western blot analysis of
E2F5 protein levels after immunoprecipitation-mediated enrichment in H1299 cells transfected with 5 nM of miR-128-2 mimic or control mimic for 48 h. E2F5 protein was
evidenced by using E-19 antibody from Santa Cruz Biotechnology. (c) Analysis of E2F5 protein expression by immunocytochemistry in H1299 cells transfected with 5 nM of
miR-128-2 mimic or control mimic was performed using anti-E2F5 antibody from Santa Cruz Biotechnology (E-19). The graph (left panel) shows the percentage of E2F5-
positive nuclei. The right panel shows a representative image of E2F5 protein staining. (d) Renilla luciferase activity of E2F5-30-UTR reporter gene in H1299 cells transiently
transfected with 5 nM of miR-128-2 mimic or control mimic. An equal amount of pGL3-basic firefly luciferase reporter vector was added to each transfection mixture. Cell
extracts were prepared 48 h later and subjected to determination of Renilla and firefly luciferase activities. Results are presented as Renilla activity relative to total proteins and
firefly activity. Histograms show the mean of three experiments performed in duplicate. (e) Western blot analysis of E2F5 protein levels after immunoprecipitation-mediated
enrichment in H1299-p53His175 inducible cells upon 48 h of ponasterone treatment. E2F5 protein was evidenced by using E-19 antibody from Santa Cruz Biotechnology. (f)
p53 and p21waf1 proteins levels in H1299-p53His175 inducible cells upon 48 h of ponasterone treatment. (g) Mir-128-2 relative expression levels were evaluated by qRT-PCR
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Altogether these findings highlight p21waf1 protein as a
mediator of miRNA-128-2-induced chemoresistance.
Discussion
In the present study, we explored the possibility that mutant
p53 proteins exert gain-of-function activity through the
modulation of miRNA expression in NSCLC cells. miRNAs
are important players in tumorigenesis and a differential
expression of specific signatures of miRNAs in the tumor
tissues compared with their normal counterparts has emerged
in almost all cancer types so far analyzed, including lung.28,29
We evidenced that mutant p53R175H is able to induce
the expression of miR-128-2 by transactivating the promoter
Figure 5 miR-128-2 induces p21waf1 expression and cytoplasmic localization. (a) RT-PCR analysis of p21waf1 mRNA levels in H1299 and A459 cells upon 48 h of
transfection with 5 nM miR-128-2 mimic or control mimic and in H1299-p53His175 inducible cells upon 48 h of ponasterone treatment. (b) p21waf1 protein levels in H1299 and
A459 cells after 48 h of miR-128-2 expression and in H1299-p53His175 inducible cells upon 48 h of ponasterone treatment. (c) Cross-linked chromatin from H1299 cells after
48 h of transfection with 5 nM miR-128-2 mimic or control mimic was immunoprecipitated with antibody (Ab) to E2F5 or in the absence of antibody, and analyzed by PCR with
primers specific for the region of p21waf1 promoter enclosing the E2F binding site. (d) p21waf1 protein levels in H1299-p53His175 inducible cells transiently transfected with
decoy-miR-128-2 or decoy-control vectors and treated for 48 h with ponasterone. (e) Analysis of p21waf1 and cyclin D1 proteins stability in H1299 cells transfected for 48 h with
5 nM miR-128-2 mimic or control mimic and treated with 20 mg/ml cycloheximide (CHX) to inhibit new protein synthesis for the times indicated. Protein levels of p21waf1, cyclin
D1 and glyceraldehyde 3-phosphate dehydrogenase (gapdh) were analyzed by immunoblot. (f) Cellular localization of p21waf1 determined by cellular fractionation in H1299
and A459 cells transfected for 48 h with 5 nM miR-128-2 mimic or control mimic. Equal amounts (40 mg) of cytoplasmic fraction and nuclear fractions from each sample were
analyzed by 12% SDS-PAGE. Gapdh and Histone H1 were used as markers of the cytoplasmic and nuclear fraction, respectively. (g) Subcellular localization of endogenous
p21waf1 in A459 cells transiently transfected for 48 h with 5 nM miR-128-2 mimic or control mimic visualized by immunofluorescence using anti-p-p21 antibodies. DNA staining
with DAPI and a merged view of green and blue channels of the same field is shown (merge)
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of its host gene, ARPP21. The transcriptional induction of
miR-128-2 by mutant p53R175H results in the increased
chemoresistance of cancer cells.
Additional miRNAs have been previously shown to mod-
ulate sensitivity to chemotherapeutic treatments. The cluster
comprising miR-183/miR-96/miR-182 for example is upregu-
lated in cells characterized by multidrug resistance.36 miR-182
was also shown to target BRCA1 impeding DNA repair in
breast cancer cells.37 In lung cancer, a crucial role in
chemoresistance is played by miR-630, which is responsible
for the blocking of p53 activation and cleavage of caspases in
response to cisplatin treatment.38
It is well established that cancer cells carrying endogenous
conformational p53 mutant proteins are less sensitive to
chemotherapeutic treatments compared with cells carrying
p53 gene deletions. By exogenous expression or decoy-
mediated depletion of miR-128-2 we could assess that
miR-128-2 is able to confer resistance to different chemo-
therapeutic agents, such as 5-FU and DOXO, independently
from the presence of mutant p53. Mutant p53 then seems to
be involved in the transactivation of a miRNA that per se confers
resistance to chemotherapeutic agents. As the miR-128-2
confers chemoresistance it is reasonable to speculate that
many additional oncogenic stimuli, other than p53 mutation,
could lead to miR-128-2 induction during lung tumorigenesis
(Figure 7).
Importantly, miR-128-2 expression causes p21waf1 upregu-
lation and accumulation in the cytoplasm, a feature that was
repeatedly associated with an anti-apoptotic effect of p21waf1.
p21waf1 induction occurs as a result of the translational
inhibition of the transcriptional repressor E2F5 by miR-128-2.
E2F5-30-UTR is indeed directly controlled by miR-128-2 and
the decrease of E2F5 protein level after miR-128-2 expres-
sion leads to its detachment from p21waf1 promoter and to the
increase of p21waf1 mRNA and protein levels (Figure 7).
Several studies have pointed out that, in addition to being
an inhibitor of cell proliferation, p21waf1 acts as an inhibitor of
apoptosis in a number of systems; indeed p21waf1 phosphor-
ylation frequently pairs with its cytoplasmic localization and
anti-apoptotic function, as observed in different tumor types,
and correlates with an increased chemoresistance.39–41
Indeed, Akt phosphorylation at threonine 145 induces
p21waf1 cytoplasmic localization and its subsequent binding
to pro-caspase-3 that prevents pro-casapase-3 cleavage and
Figure 6 miR-128-2-induced cytoplasmic p21waf1 promotes chemoresistance.
(a) Colocalization of p21waf1 and caspase-3 in A459 cells transfected for 48 h
with miR-128-2 mimic or control mimic stained with anti-p21 (green) and anti-
caspase-3 (red) antibodies. A merged view of green and red channels of the same
field is shown (merge). (b) Amounts of cleaved caspase-3 analyzed by western
blot using a specific antibody to caspase-3 and full-length pro-caspase-3 in H1299
and A459 cells transiently transfected for 48 h with 5 nM miR-128-2 mimic or
control mimic and treated for 24 h with 10 mg/ml cisplatinum (CDDP) and 50 mM
5-fluorouracil (5-FU), respectively. (c) H1299-p53His175 inducible cells were
transiently transfected with decoy-miR-128-2 or decoy-control vectors and then
induced for 48 h with ponasterone and treated for 24 h with 2.5mM DOXO. Amounts
of cleaved PARP fragment (p85), p21waf1, p53 and gapdh proteins were analyzed
by immunoblot
Figure 7 Schematic representation of the proposed molecular mechanism.
Mutant p53 protein is able to induce miR-128-2 expression that in turn determines
p21waf1 upregulation, in part by inhibiting E2F5 transcriptional repressor activity on
p21waf1 promoter, and its localization in the cytoplasm where it exerts its anti-
apoptotic function by binding to pro-caspase-3
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blocks the apoptotic response.33 In agreement with these
evidences, we observed that miR-128-2-induced p21waf1
protein is localized in the cytoplasm, where it binds to pro-
caspase-3. Themolecular mechanism responsible for p21waf1
protein cytoplasmic localization following miR-128-2 expres-
sion needs to be identified yet. It is reasonable to assume that
miR-128-2 modulates the expression and activation of
additional proteins involved in the control of p21waf1 sub-
cellular localization. In addition to the cytoplasmic transloca-
tion and increase in the stability of p21waf1, we observed
an increased half-life of cyclin D1. This led us to speculate
that the PI3K/Akt pathway is likely involved in response to
miR-128-2. It was indeed shown that PI3K/Akt activation results
in the inhibition of GSK3b kinase, the major responsible of
cyclin D1 phosphorylation and subsequent degradation.
Activation of PI3K/Akt signaling then may lead to the stabi-
lization of cyclin D1, which could in turn participate to p21waf1
protein stabilization after miR-128-2 expression. As mentioned
above, Akt activation has been also shown to phosphorylate
p21waf1, leading to its cytoplasmic localization.
We provide evidence that miR-128-2 induction contributes
to the well-established chemoresistance activity mediated by
mutant p53. Of relevance, mutant p53-driven chemoresis-
tance is counteracted by the repressive function of E2F5.
Taken together, these findings with those showing that mutant
cooperates with E2F1 in the promotion of neoangiogenesis,12
highlight a close link between gain-of-function mutant p53
proteins and E2F family members.
As mentioned above, mutant p53R175H expression leads
to the induction of both miR-128-2 and ARPP21 expression.
By using a chromatin immunoprecipitation approach, we
observed that mutant p53 binds three different regions of the
putative promoter region of ARPP21 gene. Mutant p53 has
been repeatedly reported to function as an oncogenic
transcription factor.42,43 Mutant p53 proteins can indeed be
recruited in large transcriptional complexes enabling their
recruitment to the promoters of cancer-related target genes,
such as Fas/CD91, Egr1, Cdk1 and cyclin B2, Id2, Id4,
TGFb1, HIRA and many others. Our study provides the first
evidence of the ability of the transcriptional complexes
containing mutant p53 to modulate the expression of a
miRNA. Several transcription factors can cooperate with
mutant p53 in transcription (e.g., NF-Y, NF-kB, E2F1, VDR)
and many of their binding sites are present on ARPP21
promoter. The mutant p53-containing transcriptional com-
plexes recruited on ARPP21 promoter deserve further
investigation.
As each miRNA controls the expression of a plethora of
target mRNAs, the identification of miRNAs targeted by
mutant p53 opens new opportunities to develop molecular
tools aimed at interfering with mutant p53 oncogenic function.
Materials and Methods
Cell cultures and treatments. H1299, H1299 clone 41, H1299 clone 23 and
H1299 clone pIND cells were cultured and induced as previously reported.12,20
Human epithelial non-small-cell lung adenocarcinoma A459 cells were cultured in
DMEM medium (Invitrogen, Carlsbad, CA, USA) with 10% (v/v) FCS. For
chemoresistance experiments, cells were treated with CDDP (Pfizer, New York,
NY, USA), DOXO (Ebewe Pharma, Kundl, Austria) and 5-FU (Teva, Petach Tikva,
Israel) at the indicated concentrations for 24 h. For protein stability assays, cells
were treated with 20mg/ml cycloheximide (Sigma-Aldrich, St. Louis, MO, USA) at
the indicated times.
Plasmids and transfections. Reporter vector A-Luc and B-Luc were
generated by cloning 1474 bp and 847 bp, respectively, from the ARPP21 promoter
in the BamHI site of Po-LUC vector. Mutant p53 exogenous expression was
performed using pcDNA3-p53-R175H vector. Reporter vector pRL-TK-E2F5-30-
UTR was generated by cloning 653 bp from the E2F5-30-UTR region in the XbaI site
of HSV-pRL-TK (Promega, Madison, WI, USA). Primers used for the amplifications
are listed in Supplementary Table 1.
miR-128-2 activity was abrogated using a lentiviral vector named TWEEN
30-UTR (TW3), enclosing a multicloning site in the 30-UTR of an EGFP reporter gene,
where we inserted two antisense sequences for miR-128-2 (decoy-miR-128-2
vector). For mature miR-128-2 expression, we used 5 mM miRNA Mimics
(Dharmacon, Lafayette, CO, USA): hsa-miR-128-2-mimic and negative control
#1. H1299 and A459 cells were transfected with Lipofectamine 2000 following the
manufacturer’s instructions (Invitrogen).
Cells extracts and western blot. Cells were lysed in hypotonic lysis buffer
(10 mM Tris pH 8; 120 mM NaCl; 15% glycerol; 0.5% Nonidet P-40; fresh DTT
2.5 mM. and fresh protease inhibitors). Extracts were sonicated for 20 s and
centrifuged at 14 000 r.p.m. for 15 min to remove cell debris. Protein concentra-
tions were determined by colorimetric assay (Bio-Rad, Hercules, CA, USA).
Western blotting was performed using the following primary antibodies: mouse
monoclonal anti-GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA, USA); mouse
monoclonal anti-tubulin (Santa Cruz Biotechnology); mouse monoclonal anti-hsp-70
(Santa Cruz Biotechnology); goat polyclonal anti-histone-H1 (Santa Cruz
Biotechnology); mouse monoclonal anti-p53 (DO1); rabbit polyclonal anti-E2F5
(Santa Cruz Biotechnology, E-19); rabbit polyclonal anti-E2F5 (Abgent, San Diego,
CA, USA); rabbit polyclonal anti-p21 (Santa Cruz Biotechnology); rabbit polyclonal
anti-PARP (Cell Signaling, Danvers, MA, USA); mouse monoclonal anti-caspase-3
(Alexis, San Diego, CA, USA); mouse monoclonal anti-cyclin D1 (Invitrogen).
Secondary antibodies used were goat anti-mouse, goat anti-rabbit and rabbit
anti-goat, conjugated to horseradish peroxidase (Amersham Biosciences,
Piscataway, NJ, USA). Immunostained bands were detected by chemilumine-
scent method (Pierce, Rockford, IL, USA).
Nucleocytoplasmic extracts preparation. After pelleting and removal
of D-PBS, cells were allowed to swell for 10 min on ice in a hypotonic buffer
(10 mM HEPES-KOH pH 7.9; 1.5 mM MgCl2; 10 mM KCl; 0.5 mM dithiothreitol;
0.2 mM phenylmethylsulfonyl fluoride) followed by vortexing and centrifugation.
The supernatants were removed and used as cytosolic fraction and the pellet
(corresponding to the nuclei) was resuspended in a high salt buffer (20 mM HEPES-
KOH pH 7.9; 25% glycerol; 0.42 M NaCl; 1.5 mM MgCl2; 0.2 mM EDTA; 0.5 mM
dithiothreitol; 0.2 mM phenylmethylsulfonyl fluoride) for 30 min to extract nuclear
proteins.
Immunoprecipitation. Cells were lysed in lysis buffer (50 mM Tris-HCl pH
7.5; 150 mM NaCl; 5 mM EDTA; 10 mM MgCl2; 1 mM KCl; 0.5% NP40). For each
immunoprecipitation, 1 mg of rabbit aE2F5 antibody (Santa Cruz Biotechnology,
E-19) and 1 mg of rabbit IgG as control were used. Precleared extracts were
incubated with protein A/G-Agarose beads (Pierce) in lysis buffer containing 0.05%
BSA and antibodies, under constant shaking at 41C over night. After incubation,
agarose bead-bound immunocomplexes were rinsed with lysis buffer and eluted in
50ml of SDS sample buffer for western blotting.
RNA extraction and reverse transcriptase reaction. Cells were
harvested in TRIzol reagent (Invitrogen) and total RNA was isolated as per the
manufacturer’s instructions. Five micrograms of total RNA were reverse-transcribed
at 371C for 60 min in the presence of random hexamers and Moloney murine
leukemia virus reverse transcriptase (Invitrogen). PCR analyses were carried out by
using oligonucleotides specific for the genes listed in Supplementary Table 2.
ARPP21 and GAPDH expressions were measured by real-time PCR using the Sybr
Green assay (Applied Biosystems, Carlsbad, CA, USA) on a StepOne instrument
(Applied Biosystems). RTq-PCR quantification of miRNA expression was performed
using TaqMan MicroRNA Assays (Applied Biosystems) according to the
manufacturer’s protocol. RNU6B, RNU19, RNU44, RNU49 and RNU66 were
used as endogenous controls to standardize miRNA expression. All reactions were
performed in duplicate. Taqman probes for the following miRNAs were purchased
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from Applied Biosystems: hsa-miR-17-5p, hsa-miR-21, hsa-miR-25, hsa-miR-29b,
hsa-miR-30c, hsa-miR-32, hsa-miR-107, hsa-miR-128-2, hsa-miR-155, hsa-miR-
199a, hsa-miR-221.
Luciferase assays. Assay in H1299-p53His175 inducible cells: cells were
co-transfected in a 60-mm plate with 500 ng of ARPP21-promoter-A-luc or ARPP21-
promoter-B-luc reporter constructs and treated with Pon-A for 24 or 48 h. Assay in
H1299 cells were co-transfected in a 60-mm plate with 500 ng of ARPP21-promoter-
A-luc or ARPP21-promoter-B-luc reporter constructs together with increasing
amounts of pCDNA3-p53His175 (750 ng to 3 mg). For normalization of transfection
efficiency, 500 ng of pRL-TK reporter (Promega), constitutively expressing the
Renilla luciferase, was included. After 48 h, cells were lysed and assayed for
luciferase activity using the Dual Luciferase kit (Promega) to measure both
Renilla and firefly luciferase activities. 30-UTR reporter assays: H1299 cells were
co-transfected in a 60-mm plate with 500 ng of pRL-TK-E2F5-30-UTR or pRL-TK (as
control) constructs together with 5 nM miR-128-2 mimic or control mimic. An equal
amount of pGL3-basic firefly luciferase reporter vector was added to each
transfection mixture. Cell extracts were prepared 48 h later and subjected to
determination of Renilla and firefly luciferase activities using the Dual Luciferase kit.
Formaldehyde cross-linking and chromatin immunoprecipitation.
Formaldehyde cross-linking and chromatin immunoprecipitations were performed as
described.18 The chromatin solution was immunoprecipitated with sheep anti-p53
serum (Ab7, Calbiochem, San Diego, CA, USA), anti-p53 (DO1), anti-E2F-5 (Santa
Cruz, E-19) or no antibody as negative control. Cyclin B1 first intron was amplified as
negative control as described.18
Primers used for the amplification of the different regulatory regions are listed in
Supplementary Table 3.
Cell cycle analysis. Samples were collected over the indicated time points
and fixed in 70% ethanol overnight. Fixed cells were treated with RNase for 20 min
before addition of 5 mg/ml PI and analyzed by FACS.
Immunofluorescence and immunocytochemistry. Cells were
seeded onto glass coverslips (Marienfeld laboratory glassware, Lauda-
Ko¨nigshofen, Germany) at 5 104 cells per ml in a 6-well plates, transfected and
fixed 48 h later with 4% paraformaldehyde in PBS for 30 min at room temperature
(RT). Cells were permeabilized with 1% Triton X-100 in PBS for 10 min. After
washing with PBS, the coverslips were incubated with p21 antibody (Santa Cruz
Biotechnology) and/or caspase-3 (Alexis), E2F5 (Santa Cruz Biotechnology, E-19)
diluted in 5% BSA/PBS for 1 h at RT. For immunofluorescence they were then
washed twice with 0.02% Tween-20 and 1% BSA in PBS, followed by incubation
with Alexa Flour 488 (rabbit) and Alexa Fluor 594 (mouse) conjugated secondary
antibodies (Molecular Probes Inc., Eugene, OR, USA) for 30 min at RT. After
washing three times with 0.02% Tween-20 and 1% BSA in PBS, the coverslips were
counterstained with DAPI 5 min and mounted with Vectashield (Vector Labs,
Burlingame, CA, USA). Cells were examined under a Zeiss LSM 510 laser
scanning fluorescence confocal microscope (Zeiss, Wetzlar, Germany). For
immunocytochemistry, cells were incubated with peroxidase inhibitor before
primary antibody incubation. Protein staining was revealed through DAB enzymatic
reaction while nuclei were counterstained with hematoxylin.
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